CATUG combines its core RNA-LNP CRDMO platform with selected technology, supply chain, preclinical, clinical and translational partners to help clients close critical development gaps.
Partner-enabled solution
The ecosystem is designed to support program execution without blurring client IP ownership, pipeline control, or therapeutic asset rights.
DNA, RNA, LNP, AD/QC and GMP DP.
Tools, studies, clinical and technology access.
No equity claim or downstream product rights.
Coordinated communication for complex programs.
CATUG remains accountable for its core CRDMO scope while using selected ecosystem resources to complement technology access, preclinical studies, translational coordination and program strategy.
CATUG Core Platform
Partner-Enabled Extension
Novel lipids, gene editing tools, circRNA technologies, targeting ligands and specialized delivery resources.
Qualified materials, GMP-grade reagents, consumables, equipment vendors and process-enabling resources.
Partner-enabled support for in vivo assays, biodistribution, pharmacology and tox-related studies.
Clinical CRO, hospital and translational coordination support under applicable regulatory requirements.
Partner logos can be displayed based on approval, project relevance and communication needs. This area is designed to show ecosystem depth without overcomplicating the page.
For selected programs, CATUG can support translational coordination by connecting CMC execution with partner-enabled preclinical, clinical and institutional resources.
CATUG can support CMC execution, GMP material readiness, technical documentation, manufacturing timelines, QC release planning and coordination with approved external partners.
Sponsors, clinical institutions, CROs and investigators remain responsible for clinical design, ethics submissions, patient-related decisions and regulated clinical execution.
IIT and clinical activities are conducted under applicable institutional, ethical and regulatory requirements. CATUG supports CMC execution and partner coordination, while respecting client IP, sponsor ownership, institutional responsibilities and medical decision-making boundaries.
CATUG can help evaluate whether your program may benefit from technology access, small nucleic acid synthesis / GMP support, preclinical / tox partners, targeting ligand resources, clinical coordination or IIT-supporting ecosystem resources.